> Three Months Ended
March 31,
2008 2007
United United
States Europe Total States Europe Total
Sales:
PROVIGIL $198,469 $14,766 $213,235 $188,727 $12,562 $201,289
GABITRIL 11,131 2,293 13,424 13,884 2,336 16,220
CNS 209,600 17,059 226,659 202,611 14,898 217,509
ACTIQ 37,517 12,203 49,720 57,157 8,571 65,728
Generic OTFC 27,318 - 27,318 34,020 - 34,020
FENTORA 38,933 - 38,933 31,690 - 31,690
AMRIX 9,768 - 9,768 - - -
Pain 113,536 12,203 125,739 122,867 8,571 131,438
Oncology 5,188 22,270 27,458 3,991 19,290 23,281
Other 13,527 40,514 54,041 13,181 38,470 51,651
$341,851 $92,046 $433,897 $342,650 $81,229 $423,879
%
Increase
(Decrease)
United
States Europe Total
Sales:
PROVIGIL 5% 18% 6%
GABITRIL (20%) (2%) (17%)
CNS 3% 15% 4%
ACTIQ (34%) 42% (24%)
Generic OTFC (20%) 0% (20%)
FENTORA 23% 0% 23%
AMRIX
'/>"/>
SOURCE Cephalon, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine news :1.
Cephalon Appoints Gerald J. Pappert as General Counsel2.
inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.3.
Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference4.
Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer5.
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia6.
Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs7.
Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 20098.
Nu Skin Enterprises Reports First-Quarter 2008 Results9.
Cardinal Health Reports Third Quarter Results10.
BioMed Realty Trust Reports First Quarter 2008 Financial Results11.
Cardiac Science Reports Strong Q1 Results